Syndax shares slump 16% after axatilimab misses mid-stage trial goal
Syndax Pharmaceuticals said its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis. Shares fell 15% after hours on Monday.
Syndax Pharmaceuticals (SNDX) shares fell 15% after hours on Monday after the company reported that axatilimab, its experimental drug for idiopathic pulmonary fibrosis, missed the primary goal of a mid-stage study. The progressive disease causes lung scarring and is often fatal.